Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
D000107:Acetylation; D000380:Agranulocytosis / Q000139:chemically induced; D000636:Aminosalicylic Acids / Q000097:blood; D000743:Anemia, Hemolytic / Q000139:chemically induced; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D005965:Glucuronates / Q000097:blood; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010641:Phenotype; D010859:Pigmentation Disorders / Q000139:chemically induced; D011725:Pyridines / Q000097:blood / Q000378:metabolism; D012871:Skin Diseases / Q000139:chemically induced; D013424:Sulfanilamides / Q000097:blood / Q000378:metabolism*; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000636:Aminosalicylic Acids; D005965:Glucuronates; D011725:Pyridines; D013424:Sulfanilamides; D012460:Sulfasalazine